Adjuvant Durvalumab for Esophageal Cancer
Adjuvant Durvalumab vs Placebo for 1 year after complete resection of esophageal cancer following neoadjuvant CCRT.
Esophageal Cancer
DRUG: Durvalumab|DRUG: Placebo
Disease-free survival, 1 year
Adjuvant Durvalumab vs Placebo for 1 year after complete resection of esophageal cancer following neoadjuvant CCRT.